Pharma Report on Psoriasis – Pipeline Review, H2 2020

Source: https://www.researchbymarkets.com/report/psoriasis-pipeline-review-h2-2020-645843.html

Psoriasis – Pipeline Review, H2 2020

Summary

Psoriasis – Pipeline Review, H2 2020, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights

Psoriasis – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 25, 38, 63, 2, 150, 40 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
– The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
3SBio Inc
AbbVie Inc
Abcentra LLC
AbClon Inc
Abeome Corp
Abivax SA
Accuitis Pharmaceuticals Inc
Aclaris Therapeutics Inc
Actinobac Biomed Inc
ADiTx Therapeutics Inc
Aerie Pharmaceuticals Inc
Affibody AB
Affilogic SAS
Akeso Inc
Aldeyra Therapeutics Inc
Allergy Therapeutics Plc
Allianz Pharmascience Ltd
Almirall SA
AltruBio Inc
Aluda Pharmaceuticals Inc
Alvotech ehf
AmDerma Pharmaceuticals LLC
Amgen Inc
Amicogen Inc
AnaptysBio Inc
Annji Pharmaceutical Co Ltd
AntalGenics SL
AnTolRx Inc
Apidel SA
Apimeds Inc
Applied Biology Inc
Arbor Pharmaceuticals LLC
Arcutis Inc
Arrien Pharmaceuticals LLC
AstraZeneca Plc
Athenex Inc
Atlantic Bio Sci LLC
Aurigene Discovery Technologies Ltd
Avicanna Inc
Avidin Biotechnology Ltd
Bayer AG
Beijing Fogangren Bio-Pharm Tech Co Ltd
Beijing Guiqianjin Medical Technology Co Ltd
Beijing Northland Biotech Co Ltd
Beijing SH Bio-Tech Corp
Better Life Pharmaceuticals Inc
Bio-Thera Solutions Ltd
BioApex sro
Biocon Ltd
BioLingus AG
Biomendics LLC
Biomimetix JV LLC
BioXpress Therapeutics SA
Biozeus Pharmaceutical SA
BirchBioMed Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Botanix Pharmaceuticals Ltd
Brickell Biotech Inc
Bristol-Myers Squibb Co
c-a-i-r Biosciences GmbH
C4X Discovery Holdings Plc
Can-Fite BioPharma Ltd
Canvax Biotech SL
CellionBioMed Inc
Celltrion Inc
Celon Pharma SA
CheckPoint Immunology Inc
ChemoCentryx Inc
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chiesi Farmaceutici SpA
Coegin Pharma AS
Coherus BioSciences Inc
Compugen Ltd
Crescita Therapeutics Inc
Curapel Ltd
Cythera Inc
Cytodyn Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dalriada Therapeutics Inc
DelArrivo Inc
Denali Therapeutics Inc
Dermavant Sciences Inc
DiCE Molecules SV Inc
DM Bio Ltd
DNX Biopharmaceuticals Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Eli Lilly and Co
ELORAC Inc
Emeriti Pharma AB
Enzychem Lifesciences Corp
Eolo Pharma
Escalier Biosciences BV
Eternity Bioscience Inc
Evelo Biosciences Inc
Exicure Inc
FunPep Co Ltd
FYB202 GmbH & Co KG
Galapagos NV
Galderma SA
Galectin Therapeutics Inc
Genentech USA Inc
GeneScience Pharmaceuticals Co Ltd
Genesen Co Ltd
Genfit SA
Genrix (Shanghai) Biopharmaceutical Co Ltd
GlaxoSmithKline Plc
GlycoMar Ltd
Helix BioMedix Inc
Hengenix Biotech Inc
HitGen Inc
Huabo Biopharm Co Ltd
Hualan Biological Engineering Inc
Hydra Biosciences Inc
ILC Therapeutics Ltd
Iltoo Pharma
IMGENEX India Pvt Ltd
Immune Pharmaceuticals Inc
ImmuneMed Inc
Immungenetics AG
Immunic Inc
Immunwork Inc
Impetis Biosciences Ltd
InnoCare Pharma Ltd
Innovimmune Biotherapeutics Inc
InSight Biopharmaceuticals Ltd
Inspyr Therapeutics Inc
Instituto Biomar SA
Io Therapeutics Inc
Istesso Ltd
Japan Tobacco Inc
JHL Biotech Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
JS InnoPharm (Shanghai) Ltd
Jubilant Therapeutics Inc
Kadmon Corp LLC
Kang Stem Biotech Co Ltd
Kangpu Biopharmaceuticals Ltd
Kine Sciences
Krystal Biotech Inc
Kv1.3 Therapeutics
Kymab Ltd
Lead Pharma Holding BV
Leo Pharma AS
Link Health Group
Lipidor AB
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Lycera Corp
Mabpharm Ltd
Machavert Pharmaceuticals LLC
Maruho Co Ltd
Matrisys Bioscience Inc
MC2 Therapeutics AS
Merck KGaA
Metrion Biosciences Ltd
MetrioPharm AG
Mical Pharmaceuticals LLC
Midatech Pharma Plc
Mycenax Biotech Inc
Nektar Therapeutics
Nepsone ehf
NeuClone Pty Ltd
Nichi-Iko Pharmaceutical Co Ltd
Nimbus Therapeutics LLC
North China Pharmaceutical Group New Drug Research and Development Co Ltd
NovaLead Pharma Pvt Ltd
Novartis AG
Numab Therapeutics AG
OncoSynergy Inc
One World Cannabis Ltd
Orphagen Pharmaceuticals Inc
OSE Immunotherapeutics
P & S Nano Ltd
Palo BioFarma SL
Panaxia Pharmaceutical Industries Ltd
Par’Immune SAS
Pfizer Inc
Pharmapraxis
Philogen SpA
Polpharma Biologics
PRCL Research Inc
Precigen ActoBio Inc
Principia Biopharma Inc
Progenra Inc
Promethera Biosciences SA
Protein Foundry LLC
Protheragen Inc
Provectus Biopharmaceuticals Inc
Pyramid Biosciences Inc
Reata Pharmaceuticals Inc
Regeneus Ltd
Regranion LLC
Reliance Life Sciences Pvt Ltd
Revive Therapeutics Ltd
Rheos Medicines Inc
Rigel Pharmaceuticals Inc
RNAx Ltd
Samumed LLC
Sareum Holdings Plc
SBI Biotech Co Ltd
Servatus Ltd
SFA Therapeutics LLC
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shulov Innovative Science Ltd
Siam Bioscience Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sienna Biopharmaceuticals Inc
Singh Biotechnology LLC
Sinocelltech Ltd
siRNAgen Therapeutics Corp
Sol-Gel Technologies Ltd
Soligenix Inc
Sparrow Pharmaceuticals Inc
Spherium Biomed SL
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd
Sun Pharmaceutical Industries Ltd
Sunny BioDiscovery Inc
Suzhou Connect Biopharmaceuticals Ltd
Syntrix Biosystems Inc
Taro Pharmaceuticals USA Inc
Temisis Therapeutics
Tianjin Ever Union Biotechnology Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
UCB SA
Union Therapeutics AS
V Clinbio LLC
Vidasym Inc
Visionary Pharmaceuticals Inc
Viva Vision Biotech
Voronoi Group
vTv Therapeutics Inc
Welichem Biotech Inc
Wellstat Therapeutics Corp
WntResearch AB
Wuhan Institute of Biological Products Co Ltd
Xbrane Biopharma AB
Zai Lab Ltd
Zhejiang Hisun Pharmaceutical Co Ltd


For queries regarding this report: https://www.researchbymarkets.com/sample-request/645843

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.